Diseases, Conditions, Syndromes

Study uncovers new biological marker for scleroderma

A cross-disciplinary University of Alberta research team has uncovered a biological marker for scleroderma that can predict which patients will develop severe disease and could also lead to new treatments.

Immunology

Making immunotherapy safe for AML

Acute myeloid leukemia (AML), the second most common leukemia in children, is hard to treat and has a five-year survival rate of just 65 to 70%, according to the American Cancer Society. While immunotherapies like monoclonal ...

page 1 from 26